Bank of Montreal Can increased its position in shares of Emergent Biosolutions Inc (NYSE:EBS) by 3.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 94,445 shares of the biopharmaceutical company’s stock after purchasing an additional 3,163 shares during the period. Bank of Montreal Can’s holdings in Emergent Biosolutions were worth $4,390,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EBS. Ameritas Investment Partners Inc. increased its position in shares of Emergent Biosolutions by 23.2% during the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 587 shares during the period. First Quadrant L P CA bought a new stake in shares of Emergent Biosolutions during the third quarter valued at approximately $157,000. Meeder Asset Management Inc. increased its position in shares of Emergent Biosolutions by 94.7% during the third quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 2,302 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Emergent Biosolutions during the third quarter valued at approximately $191,000. Finally, SG Americas Securities LLC bought a new stake in shares of Emergent Biosolutions during the third quarter valued at approximately $202,000. Institutional investors and hedge funds own 74.31% of the company’s stock.
In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 20,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $45.99, for a total value of $919,800.00. Following the sale, the chief executive officer now directly owns 224,134 shares in the company, valued at $10,307,922.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Zsolt Harsanyi sold 7,000 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $42.47, for a total value of $297,290.00. Following the completion of the sale, the director now owns 37,077 shares in the company, valued at $1,574,660.19. The disclosure for this sale can be found here. Insiders sold 165,722 shares of company stock worth $7,219,341 over the last quarter. Company insiders own 16.50% of the company’s stock.
A number of research firms have recently issued reports on EBS. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 11th. Chardan Capital boosted their price objective on Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Finally, Goldman Sachs Group began coverage on Emergent Biosolutions in a research report on Wednesday, January 24th. They set a “neutral” rating and a $55.00 price objective on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $51.00.
Shares of Emergent Biosolutions Inc (NYSE EBS) opened at $45.64 on Tuesday. Emergent Biosolutions Inc has a 1 year low of $27.94 and a 1 year high of $51.25. The firm has a market capitalization of $1,970.00, a price-to-earnings ratio of 28.53, a price-to-earnings-growth ratio of 0.98 and a beta of 1.32. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46.
Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm had revenue of $149.43 million for the quarter, compared to analysts’ expectations of $124.55 million. During the same period in the prior year, the business posted $0.56 earnings per share. The business’s revenue was up 4.6% compared to the same quarter last year. equities research analysts anticipate that Emergent Biosolutions Inc will post 1.7 EPS for the current fiscal year.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.